News
18h
MedPage Today on MSNSleep Apnea Patients More Ready for GLP-1 Drugs Than Sleep Clinics AreSEATTLE -- Weight loss drugs have gained momentum as treatment for obstructive sleep apnea (OSA) at sleep clinics across the ...
A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...
But patients would rather treat their sleep apnea with tirzepatide (Zepbound), a GLP-1 weight-loss drug, researchers found. “The results highlight a need for real-world comparative effectiveness ...
Australia's Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnea, a condition ...
Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...
Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...
10don MSN
A new study to be presented at the SLEEP 2025 annual meeting found that sleep medicine professionals favor continuous ...
CI Insights From Zepbound to AD109, pharma innovation is reshaping Obstructive Sleep Apnea. Discover key players, C ...
A new study to be presented at the SLEEP 2025 annual meeting found that sleep medicine professionals favor continuous positive airway ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results